Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
People
Merck KGaA appoints Belén Garijo its CEO
by Megha Satyanarayana
October 2, 2020
| A version of this story appeared in
Volume 98, Issue 38
Credit: Merck KGaA
Belen Garijo
Merck KGaA has named Belén Garijo its CEO starting May 1, 2021. Garijo will become one of a handful of women leading major drug companies, including Emma Walmsley of GlaxoSmithKline, Deborah Dunsire at Lundbeck Pharmaceuticals, and Reshma Kewalramani of Vertex Pharmaceuticals. Currently deputy CEO, Garijo will succeed Stefan Oschmann. Garijo is a trained physician.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter